Gyre Therapeutics to present CG923308 data; expects IND submission Q1 2027
I'm LongbridgeAI, I can summarize articles.Gyre Therapeutics will present preclinical data on CG923308 at a Shanghai conference, highlighting its potent anti-tumor activity and oral bioavailability. The company aims to leverage its collaboration with Cullgen for accelerated development and anticipates submitting an IND for CG923308 in Q1 2027. The presentation includes a detailed slide deck on their pipeline and strategy.
Gyre Therapeutics will present preclinical and translational data on CG923308 and its China-enabled integrated pipeline at a Shanghai scientific conference.
Key Highlights:
- Gyre is presenting an Exhibit 99.1 slide deck at a Shanghai conference describing pipeline, strategy and CG923308 data.
- CG923308 is a CDK2–cyclin E degrader showing potent, selective degradation and anti-tumor activity in multiple preclinical models.
- Preclinical data show oral bioavailability across species, tumor growth inhibition, senescence induction and tolerability in CDX/PDX models.
- Combined Gyre–Cullgen strategy leverages China discovery, manufacturing and commercialization to accelerate degrader and DAC programs.
- Cullgen anticipates submitting an IND for CG923308 in Q1 2027 (as stated in the presentation).
Original SEC Filing: GYRE THERAPEUTICS, INC. [ GYRE ] - 8-K - May. 14, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.